CN105920660B - Composition and preparation for treating chronic wounds - Google Patents
Composition and preparation for treating chronic wounds Download PDFInfo
- Publication number
- CN105920660B CN105920660B CN201610352596.0A CN201610352596A CN105920660B CN 105920660 B CN105920660 B CN 105920660B CN 201610352596 A CN201610352596 A CN 201610352596A CN 105920660 B CN105920660 B CN 105920660B
- Authority
- CN
- China
- Prior art keywords
- group
- composition
- arginine
- propylene glycol
- xanthan gum
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0009—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form containing macromolecular materials
- A61L26/0023—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/0066—Medicaments; Biocides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L26/00—Chemical aspects of, or use of materials for, wound dressings or bandages in liquid, gel or powder form
- A61L26/0061—Use of materials characterised by their function or physical properties
- A61L26/008—Hydrogels or hydrocolloids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
- A61L2300/21—Acids
- A61L2300/214—Amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
- A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
- A61L2300/412—Tissue-regenerating or healing or proliferative agents
Abstract
The invention discloses a composition and a preparation for treating chronic wounds, wherein the composition for treating chronic wounds is prepared from the following raw materials in percentage by mass: 0.1-10% of arginine or arginine hydrochloride, 0.1-10% of trehalose, 4.5-30% of xanthan gum, 5-30% of propylene glycol and 50-74.5% of water. Tests prove that the composition and the preparation have no stimulation and strong water absorption, can effectively absorb exudate, do not adhere to the wound surface, do not generate pain when removed, provide a moist healing environment for the wound, effectively promote the healing of the wound surface, and have the advantages of simple preparation method, short production period, simple prescription and low cost.
Description
Technical Field
The invention belongs to the technical field of biological medicines, and particularly relates to a composition for treating chronic wounds and a preparation containing the composition.
Background
With the rapid development of domestic economy and the improvement of the level of people, the life style of people is also greatly changed, chronic diseases come with the change, and chronic wounds are one of the chronic diseases. Chronic wounds refer to skin tissue injuries due to various causes that heal for more than 8 weeks, such as ulcerative wounds, diabetic wounds, pressure ulcers, and wounds that heal poorly after surgery.
Generally, the causes of chronic wounds are complex, mainly due to venous insufficiency, traumatic scars, wound infection and the like, while the reduction of growth factors at the wound, susceptibility of newly-grown granulation tissue to damage and imbalance of wound inhibin are the causes of delayed wound healing. Since most chronic wounds develop from acute wounds, the healing time of the chronic wounds is about 5 weeks longer than that of normal wounds, and the acceleration of the healing of the wounds by external force is of great significance to patients. In recent years, with the increasing number of chronic disease patients and chronic wound patients in China, how to improve the treatment effect of chronic wounds becomes one of the major problems facing the clinical world.
Arginine is an essential substrate for protein synthesis of all tissues in the human body, is also the only amidine donor amino acid, participates in polyamine and creatine synthesis, and is also an important participant in urea cycle. Arginine is a semi-essential amino acid in normal adults, and children and hunger, trauma and severely stressed adults synthesize very little arginine themselves and must be supplemented by exogenous sources, in which case arginine is an essential amino acid.
Disclosure of Invention
The object of the present invention is to overcome the disadvantages of the prior art and to provide a composition for the treatment of chronic wounds.
A second object of the present invention is to provide a method for preparing a composition for treating chronic wounds.
The technical scheme of the invention is summarized as follows:
the composition for treating chronic wounds is prepared from the following raw materials in percentage by mass: 0.1-10% of arginine or arginine hydrochloride, 0.1-10% of trehalose, 4.5-30% of xanthan gum, 5-30% of propylene glycol and 50-74.5% of water.
Preferably, the composition is prepared from the following raw materials in percentage by mass: 1% of arginine or arginine hydrochloride, 2% of trehalose, 4.5% of xanthan gum, 18% of propylene glycol and 74.5% of water.
The preparation method of the composition for treating chronic wounds comprises the following steps:
(1) adding arginine or arginine hydrochloride, trehalose, and water into water phase tank, mixing, heating to 80-90 deg.C, and maintaining the temperature for 20-30 min;
(2) mixing xanthan gum and propylene glycol, pouring into an emulsification tank after the xanthan gum and the propylene glycol are mixed uniformly, and heating the emulsification tank to 80-90 ℃;
(3) adding the mixture obtained in the step (1) into an emulsifying tank, homogenizing in vacuum for 5-10min, and stirring for 20-30 min;
(4) cooling to 30-40 deg.C.
Tests prove that the composition has no stimulation and strong water absorption, can effectively absorb exudate, does not adhere to the wound surface, namely does not generate pain when being removed, provides a moist healing environment for the wound, effectively promotes the healing of the wound surface, and has the advantages of simple preparation method, short production period, simple prescription and low cost.
Detailed Description
The present invention will be further described with reference to the following examples.
Example 1
The composition for treating chronic wounds is prepared from the following raw materials in percentage by mass: 0.1% of arginine, 0.1% of trehalose, 30% of xanthan gum, 5% of propylene glycol and 64.8% of water.
Example 2
The composition for treating chronic wounds is prepared from the following raw materials in percentage by mass: arginine hydrochloride 10%, trehalose 10%, xanthan gum 10%, propylene glycol 20% and water 50%.
Example 3
The composition for treating chronic wounds is prepared from the following raw materials in percentage by mass: 1% of arginine, 2% of trehalose, 4.5% of xanthan gum, 18% of propylene glycol and 74.5% of water.
Example 4
The composition for treating chronic wounds is prepared from the following raw materials in percentage by mass: 3% of arginine, 7% of trehalose, 7% of xanthan gum, 30% of propylene glycol and 53% of water.
Example 5
A process for the preparation of a composition (gel) for the treatment of chronic wounds, comprising the steps of:
(1) taking the raw materials according to the example 1;
(2) adding arginine, trehalose and water into a water phase tank, mixing, heating to 80 deg.C, and keeping the temperature for 20 min;
(3) mixing xanthan gum and propylene glycol, pouring into an emulsification tank after the xanthan gum and the propylene glycol are mixed uniformly, and heating the emulsification tank to 80 ℃;
(4) adding the mixture obtained in the step (2) into an emulsifying tank, homogenizing in vacuum for 5min, and stirring for 30 min;
(5) cooling to 30 deg.C to obtain the final product.
Example 6
A process for the preparation of a composition (gel) for the treatment of chronic wounds, comprising the steps of:
(1) taking the raw materials according to the example 2;
(2) adding arginine hydrochloride, trehalose and water into a water phase tank, mixing, heating to 90 ℃, and keeping the temperature for 30 min;
(3) mixing xanthan gum and propylene glycol, pouring the mixture into an emulsification tank after the xanthan gum and the propylene glycol are mixed uniformly, and heating the emulsification tank to 90 ℃;
(4) adding the mixture obtained in the step (2) into an emulsifying tank, homogenizing in vacuum for 10min, and stirring for 20 min;
(5) cooling to 40 deg.C to obtain the final product.
Example 7
A process for the preparation of a composition (gel) for the treatment of chronic wounds, comprising the steps of:
(1) taking the raw materials according to the example 3;
(2) adding arginine, trehalose and water into a water phase tank, mixing, heating to 85 deg.C, and keeping the temperature for 20 min;
(3) mixing xanthan gum and propylene glycol, pouring into an emulsification tank after the xanthan gum and the propylene glycol are mixed uniformly, and heating the emulsification tank to 85 ℃;
(4) adding the mixture obtained in the step (2) into an emulsifying tank, homogenizing in vacuum for 5min, and stirring for 20 min;
(5) cooling to 40 deg.C to obtain the final product.
Example 8
A process for the preparation of a composition (gel) for the treatment of chronic wounds, comprising the steps of:
(1) taking the raw materials according to the example 4;
(2) adding arginine, trehalose and water into a water phase tank, mixing, heating to 83 ℃, and keeping the temperature for 25 min;
(3) mixing xanthan gum and propylene glycol, pouring into an emulsification tank after the xanthan gum and the propylene glycol are mixed uniformly, and heating the emulsification tank to 88 ℃;
(4) adding the mixture obtained in the step (1) into an emulsification tank, homogenizing in vacuum for 6min, and stirring for 24 min;
(5) cooling to 34 deg.C to obtain the final product.
Example 9
And (3) testing:
the control used in the following tests and the preparation method thereof were as follows:
control 1 group: (1) weighing 1g of arginine, 4.5g of xanthan gum, 18g of propylene glycol and 74.5g of water;
(2) adding arginine and water into a water phase tank, mixing, heating to 85 ℃, and keeping the temperature for 20 min;
(3) mixing xanthan gum and propylene glycol, pouring into an emulsification tank after the xanthan gum and the propylene glycol are mixed uniformly, and heating the emulsification tank to 85 ℃;
(4) adding the mixture obtained in the step (2) into an emulsifying tank, homogenizing in vacuum for 5min, and stirring for 20 min;
(5) cooling to 40 deg.C to obtain the final product.
Control 2 group: (1) weighing 2g of trehalose, 4.5g of xanthan gum, 18g of propylene glycol and 74.5g of water;
(2) adding trehalose and water into a water phase tank, mixing, heating to 85 deg.C, and keeping the temperature for 20 min;
(3) mixing xanthan gum and propylene glycol, pouring into an emulsification tank after the xanthan gum and the propylene glycol are mixed uniformly, and heating the emulsification tank to 85 ℃;
(4) adding the mixture obtained in the step (2) into an emulsifying tank, homogenizing in vacuum for 5min, and stirring for 20 min;
(5) cooling to 40 deg.C to obtain the final product.
Control 3 group: (1) weighing 4.5g of xanthan gum, 18g of propylene glycol and 74.5g of water;
(2) heating propylene glycol to 85 deg.C, and maintaining the temperature for 20 min;
(3) adding xanthan gum, stirring for 25min to obtain uniform solution;
(3) cooling to 40 deg.C to obtain the final product.
Control 4 group: hydrocolloid paste (national food and drug administration character (jin) 2013 No. 3645127)
Example 10
Determination of the degree of swelling
The experimental products are weighed respectively and recorded as m1Immersing the obtained product in physiological saline for 24 hours to reach swelling equilibrium, absorbing surface moisture by using filter paper, weighing and recording as m2The swelling degree was calculated according to the following formula:
degree of swelling (%) [ (m)2-m1)/m1]*100％
TABLE 1 swelling results
| Group of | Degree of swelling (%) | Group of | Degree of swelling (%) |
| Example 5 | 90.35％ | Example 6 | 88.12％ |
| Example 7 | 96.67％ | Example 8 | 87.61％ |
| Control 1 group | 73.63％ | Control 2 group | 75.84％ |
| Control 3 group | 36.74％ | Control 4 group | 37.73％ |
Example 11
Protein adsorption Performance test
Loading different experimental groups into a separation column respectively, loading bovine serum albumin solution on the column, collecting eluate, carrying the eluate one by one every 2ml, and performing ultraviolet measurement on the eluate at 280 nm.
The absorbance was measured and represents the protein content.
TABLE 2 results of protein adsorption Capacity test
| Group of | 2ml | 6ml | 10ml | 14ml | 18ml |
| EXAMPLE 5 group | 0.02△ | 0.04△ | 0.06△ | 0.10△ | 0.06△ |
| EXAMPLE 6 group | 0.02△ | 0.04△ | 0.06△ | 0.10△ | 0.07△ |
| EXAMPLE 7 group | 0.01△ | 0.01△ | 0.04△ | 0.08△ | 0.05△ |
| EXAMPLE 8 group | 0.01△ | 0.02△ | 0.05△ | 0.09△ | 0.06△ |
| Control 1 group | 0.01 | 0.03 | 0.06 | 0.10 | 0.06 |
| Control 2 group | 0.04 | 0.06 | 0.13 | 0.20 | 0.14 |
| Control 3 group | 0.03 | 0.05 | 0.10 | 0.18 | 0.12 |
△ to control 1 group ratio P < 0.01
Example 12
Wound healing test
(A)
90 sd male rats were randomly divided into 9 groups, and on one side of the dorsal spine, hair was cut off and cleaned with physiological saline. Each group of rats was anesthetized (10% chloral hydrate anesthesia, 0.4ml/100g, i.p.), hydrocortisone (0.4ml/100g body weight) was injected through the femoral muscles, a wound with a diameter of 1.0cm was punched in the hairless area to reach the subcutaneous tissue with a punch, and then 1ml of staphylococcus aureus solution was sprayed on the periphery of each wound, one day at a time, three days continuously, and continuous intramuscular injection of hydrocortisone for three days.
The blank group was not treated, the other groups were smeared with the corresponding test articles, wound was fixedly bound with sterile gauze, dressing change was performed 1 time per day, and wound healing was observed.
(1) The wound healing rate is (original wound area-unhealed wound area)/original wound area. And (3) for both the original wound and the unhealed wound, drawing the shape of the wound by using transparent checkered paper, processing the picture by using image J software, and calculating the healing rate of the wound.
TABLE 3 wound healing Rate (%)
| Day 3 | Day 7 | Day 10 | Day 14 | Day 18 | |
| Example 5 | 18.29±0.76*△ | 49.68±0.72*△ | 59.68±0.71*△ | 78.67±0.72*△ | 98.09±0.84*△ |
| Example 6 | 17.41±0.85*△ | 50.47±0.79*△ | 59.25±0.83*△ | 79.06±0.79*△ | 97.57±0.76*△ |
| Example 7 | 18.71±0.74*△ | 51.39±0.81*△ | 60.67±0.76*△ | 80.27±0.84*△ | 99.23±0.69*△ |
| Example 8 | 18.56±0.71*△ | 50.58±0.71*△ | 61.37±0.82*△ | 79.36±0.81*△ | 98.83±0.72*△ |
| Control 1 group | 13.36±0.66* | 39.26±0.73* | 51.39±0.74* | 68.04±0.79* | 81.64±0.74* |
| Control 2 group | 12.53±0.82* | 39.57±0.82 | 51.34±0.80* | 67.64±0.87* | 81.72±0.73* |
| Control 3 group | 7.29±0.84* | 12.37±0.80* | 21.42±0.79* | 38.49±0.78* | 57.19±0.81* |
| Control 4 group | 10.74±0.87* | 25.48±0.83* | 35.64±0.80* | 58.39±0.71* | 70.95±0.38* |
| Blank control | 5.02±0.21 | 9.37±0.39 | 19.83±0.56 | 34.59±0.51 | 55.22±0.41 |
The ratio of P to the blank control group is less than 0.01, and the ratio of P to the △ to the control 1 group is less than 0.01
(2)
On days 3, 7, 10 and 14 after the administration, 1 rat in each group was decapped and sacrificed, and then the skin around the wound was clipped with forceps, cut with scissors, and observed under a microscope after the treatment.
Observation result by microscope
(II)
The main components of connective tissues formed in the process of wound repair are fibroblasts and collagen produced by the fibroblasts, the collagen forms a wound matrix and provides a support for wound epithelial cells, and the content of the collagen in the process of wound healing reflects the condition of wound healing.
Repeating the experiment, killing the rats only after the rats are loaded on the fourteenth day, clipping skin tissues (1cm x 0.5cm) of wound areas of the rats in each group, quickly placing the rats in paraformaldehyde aqueous solution for fixation, embedding paraffin according to a conventional method, slicing the rats to the thickness of about 5 microns, and measuring the type I collagen expression condition in the wound skin tissues of the rats in each group by using an IHC (IHC) color development method.
TABLE 4 results of collagen expression test
| Experimental group | Absorbance of the solution | Experimental group | Absorbance of the solution |
| EXAMPLE 5 group | 0.58±0.04*△ | Control 1 group | 0.48±0.04* |
| EXAMPLE 6 group | 0.57±0.05*△ | Control 2 group | 0.47±0.05* |
| EXAMPLE 7 group | 0.58±0.05*△ | Control 3 group | 0.44±0.06* |
| EXAMPLE 8 group | 0.59±0.05*△ | Blank control | 0.40±0.04 |
The ratio of P to blank control group is less than 0.05, and the ratio of P to △ to control 1 group is less than 0.05
Example 13
Air permeability test
The air permeability of the composition of the present invention was measured according to JIS L1096 test, and the results are shown in Table 5.
TABLE 5 air permeability test results (cubic centimeter/square centimeter/second)
| Experimental group | Experimental group | ||
| EXAMPLE 5 group | 0.0642 | Control 1 group | 0.0525 |
| EXAMPLE 6 group | 0.0710 | Control 2 group | 0.0510 |
| EXAMPLE 7 group | 0.0845 | Control 3 group | 0.0410 |
| EXAMPLE 8 group | 0.0715 | Control 4 group | 0.0455 |
Example 14
Skin irritation test
The method comprises the steps of adopting 21 healthy New Zealand white pure white rabbits with the weight not lower than 2kg, removing hairs on two sides of the spinal column of the back of an animal within 4 hours before an experiment, wherein the range is about 10cm x 10cm, dividing the rabbits into 7 groups as an experiment and observation part, smearing the experimental products on the left side, using the right side as a blank control, fixing the left side with a bandage for 4 hours after smearing the experimental products, removing the bandage after the completion, and washing away residual experimental products with distilled water. The reaction of the part where the test article was applied and the surrounding skin tissue including erythema, eschar, edema, necrosis, etc. was observed and recorded for 1h, 24h, 48h and 72h after the bandage was removed.
TABLE 5 results of skin irritation test
The above examples are only specific embodiments of the present invention, and the description thereof is specific and detailed, but not construed as limiting the scope of the present invention. It should be noted that, for a person skilled in the art, several variations and modifications can be made without departing from the inventive concept, which falls within the scope of the present invention.
Claims (2)
1. The composition for treating chronic wounds is characterized by being prepared from the following raw materials in percentage by mass: 0.1-10% of arginine or arginine hydrochloride, 0.1-10% of trehalose, 4.5-30% of xanthan gum, 5-30% of propylene glycol and 50-74.5% of water; the preparation method comprises the following steps:
(1) adding arginine or arginine hydrochloride, trehalose, and water into water phase tank, mixing, heating to 80-90 deg.C, and maintaining the temperature for 20-30 min;
(2) mixing xanthan gum and propylene glycol, pouring into an emulsification tank after the xanthan gum and the propylene glycol are mixed uniformly, and heating the emulsification tank to 80-90 ℃;
(3) adding the mixture obtained in the step (1) into an emulsifying tank, homogenizing in vacuum for 5-10min, and stirring for 20-30 min;
(4) cooling to 30-40 deg.C.
2. The composition for treating chronic wounds according to claim 1, which is prepared from the following raw materials in percentage by mass: 1% of arginine or arginine hydrochloride, 2% of trehalose, 4.5% of xanthan gum, 18% of propylene glycol and 74.5% of water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610352596.0A CN105920660B (en) | 2016-05-25 | 2016-05-25 | Composition and preparation for treating chronic wounds |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201610352596.0A CN105920660B (en) | 2016-05-25 | 2016-05-25 | Composition and preparation for treating chronic wounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105920660A CN105920660A (en) | 2016-09-07 |
| CN105920660B true CN105920660B (en) | 2020-07-28 |
Family
ID=56842186
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201610352596.0A Active CN105920660B (en) | 2016-05-25 | 2016-05-25 | Composition and preparation for treating chronic wounds |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105920660B (en) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1491645A (en) * | 2002-10-24 | 2004-04-28 | 南方医院 | Compound preparation for improving acute wound heeling for local use |
| CN1507860A (en) * | 2002-10-24 | 2004-06-30 | 南方医院 | Complex prescription preparation of local application for promoting chronic wound healing |
| WO2008157318A2 (en) * | 2007-06-13 | 2008-12-24 | Fmc Corporation | Alginate coated, polysaccharide gel-containing foam composite, preparative methods, and uses thereof |
| US20090036413A1 (en) * | 2007-07-31 | 2009-02-05 | Bill Mcanalley | Compositions, uses, and method of making wound care products from naturally occurring food ingredients |
| WO2010143196A1 (en) * | 2009-04-03 | 2010-12-16 | Cavinkare Pvt Ltd. | Novel synergistic transparent / translucent hydrogel composition; method of preparing it and a sheet / film made thereform |
| CN101890031B (en) * | 2010-07-26 | 2011-11-09 | 济南三源药业有限公司 | External medicinal composition for treating skin ulcer and preparation method thereof |
-
2016
- 2016-05-25 CN CN201610352596.0A patent/CN105920660B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN105920660A (en) | 2016-09-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Khodja et al. | Evaluation of healing activity of PVA/chitosan hydrogels on deep second degree burn: pharmacological and toxicological tests | |
| CN103394116B (en) | Hydrogel dressing capable of promoting wound healing and preparation method thereof | |
| CN106902381A (en) | Recombination human source collagen stoste, dressing and their preparation method | |
| JP5887407B2 (en) | Composite collagen sponge and method for producing the same | |
| US20070092494A1 (en) | Composition for wound healing using lyophilized skin or skin-derived collagen | |
| JP2001522877A (en) | Prolamin-vegetable polar lipid composite, process for its production and use thereof | |
| Khan et al. | A preliminary investigation of chitosan film as dressing for punch biopsy wounds in rats | |
| CN103463668A (en) | Preparation method of porous dressing of silk fibroin-calcium alginate biological wound | |
| WO2015176558A1 (en) | Composition of natural vitamin c and fish scale collagen peptide and preparation method thereof | |
| CN111481735A (en) | Medical antibacterial wound-protecting hydrogel dressing and preparation method thereof | |
| CN105327382B (en) | The method that double cross connection method prepares medical transparent polyethylene alcohol hydrogel | |
| CN105251045A (en) | Fucoidin-containing biomedical hydrogel and preparation method thereof | |
| CN104840428A (en) | Hyaluronic acid-chitosan microsphere carrying epidermal growth factor and preparation method and application of hyaluronic acid-chitosan microsphere | |
| CN115089755A (en) | Medical dressing composition of recombined fibronectin-humanized collagen with repairing effect and preparation method thereof | |
| CN107441479B (en) | Marine active peptide/chitin burn ointment for treating scald and preparation method thereof | |
| WO2015012682A2 (en) | A method for extracting collagen from aquatic animals, collagen and products containing it | |
| CN105920660B (en) | Composition and preparation for treating chronic wounds | |
| JP2005095331A (en) | Foamed body sheet containing fishskin dermal collagen and its use | |
| WO2013182551A1 (en) | Saccharide fraction from wheat, isolation process and field of use of the invention | |
| CN101797376A (en) | Preparation method of modified collagen film | |
| CN108785128A (en) | A kind of Hydrolyzed Collagen liposome and preparation method thereof of polypropylene glycol modification | |
| CN113144283A (en) | TSCP-GelMA hydrogel for promoting wound healing and preparation and application thereof | |
| CN100408091C (en) | Recombination human granul ocyte-macrophage colong stimulating factor ges and its preparation method | |
| Kuznetsova et al. | Experimental evaluation of the effectiveness of wound dressings based on biologically active substances from marine hydrobionts | |
| CN111973489B (en) | Sheep placenta extract freeze-dried powder and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20230519 Address after: 300480 No. 453 Hengshan Road, modern industrial zone, economic and Technological Development Zone, Binhai New Area, Tianjin Patentee after: TIANJIN CACHET TECHNOLOGY CO.,LTD. Address before: 300457 east of Hengshan Road, south of Changhong street and west of PUFA Xingye project, Hangu modern industrial zone, economic and Technological Development Zone, Binhai New Area, Tianjin Patentee before: TIANJIN JIASHITANG MEDICAL TECHNOLOGY CO.,LTD. |